PureTech Health Reports Phase 2b Data Showing Deupirfenidone Safe and Effective in Older IPF Patients
PureTech Health plc has reported positive Phase 2b ELEVATE IPF trial results for deupirfenidone (LYT-100), showing it is safe and effective for treating idiopathic pulmonary fibrosis (IPF) in older patients, including those aged 75 and above. The findings, presented at the CHEST 2025 Annual Meeting, indicate that deupirfenidone may fulfill an unmet need in this demographic, who often face treatment barriers due to tolerability issues.
PureTech Health plc has announced new analyses from the Phase 2b ELEVATE IPF trial evaluating deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (IPF). The results demonstrated that the safety and efficacy profile of deupirfenidone was consistent across age groups, including patients aged 75 years and older. These findings were presented at the American College of Chest Physicians (CHEST) 2025 Annual Meeting. According to PureTech, the data suggest deupirfenidone may address an unmet need in older patients with IPF, a group that has historically been less likely to receive treatment due to tolerability concerns. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PureTech Health plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251021394027) on October 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
